Boston University
Exploration of the pathogenesis and emerging therapeutic strategies in atopic dermatitis
Abstract
dc:description.abstractAtopic dermatitis (AD) is the most prevalent chronic inflammatory skin disease that significantly impacts the quality of life in 20% of children and 1-3% of adults globally. The disease is defined by a vicious itch-scratch cycle resulting in characteristic dry, scaly, and erythematous lesions of the skin. Key drivers of this cycle include mutations in the filaggrin (FLG) gene, hyperactivity of the Type 2 (Th2) immune pathway, and dysbiosis of the skin microbiome favoring Staphylococcus aureus. Overall, the pathogenesis of atopic dermatitis is multifactorial, involving genetic predisposition, environmental influences, and immune dysregulation. The complex interplay among these factors poses a challenge for precise diagnosis and treatment. A broad selection of current atopic dermatitis literature was reviewed to evaluate current and novel therapeutics in treating AD. Historically, standard of care treatments, including emollients and topical anti-inflammatory agents, have been effective in restoring the skin barrier function and alleviating the symptoms by increasing skin hydration. For example, emollients contain many hydrating factors that allow for water retention of the skin barrier. Emollients serve as preventative treatment and have limitations in their ability to restore the skin barrier when AD symptoms progress. Often regarded as the first line of treatment of AD, topical corticosteroids work towards reducing expression of pro-inflammatory mediators that are overexpressed as part of the disease course. AD patients with mild disease have found benefits with use the calcineurin inhibitor, cyclosporine, and immunosuppressants, azathioprine and methotrexate. However, due to the clinical heterogeneity of the disease and its variable severity, these conventional treatments are proving to be insufficient in treating the disease alone. Recent advances in therapeutic research have shifted towards targeted immunomodulatory strategies, including agents that inhibit key signaling pathways such as the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway. One of the most studied biologics for treating AD is dupilumab, a targeted therapy that inhibits the expression of key inflammatory cytokines Interleukin (IL)-4 and IL-13. Across numerous clinical trials, AD patients have reported significant relief in symptoms after dupilumab treatment correlated with a great reduction in scoring criteria. Nonetheless, AD pathogenesis encompasses a broad spectrum of inflammatory cytokines and mediators, indicating the need to develop therapeutics that address these alternative effectors. Following the recognition of this issue, several new therapeutics have been introduced to the market for treating AD, many of which have been previously approved for the treatment of other inflammatory diseases. These include the first approved pan-JAK inhibitor, delgocitinib; the JAK1/3 inhibitor, tofacitinib; and the JAK1 inhibitor, abrocitinib. Overall, JAK inhibitors have shown to be effective in treating moderate to severe AD with significant improvement in skin lesions as soon as four weeks after initiating treatment. The last emerging therapeutic discussed in this review is tapinarof, an aryl hydrocarbon receptor (AHR) agonist that helps modulate the effects of the AHR and aid in skin barrier repair. Continued exploration of the immunologic mechanisms underlying AD will provide critical insight into improved therapeutic approaches. Although research in these emerging therapies remains limited, current evidence suggests that they demonstrate promising efficacy in the management of more severe forms of AD and are generally well tolerated, with a low incidence of serious adverse events reported in clinical trials.
Degree
thesis:*- Name thesis:degree_name
- Master of Science
- Level thesis:degree_level
- masters
- Discipline thesis:degree_discipline
- Medical Sciences
- Grantor
- Boston University
- Year dc:date.issued
- 2026
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Zheng, Crystal
- Advisor dc:contributor.advisor
-
- Bragdon, Beth
Subjects
dc:subject × 1Rights
- Language dc:language.iso
- en_US
Identifiers
dc:identifier.*- Handle dc:identifier.uri
- https://hdl.handle.net/2144/53793